Bristol-Myers Signs $15 Billion Licensing Deal with Hengrui

US-based pharmaceutical company Bristol-Myers Squibb has signed a collaboration and licensing agreement with China's Jiangsu Hengrui Pharmaceuticals that could be worth up to $15.2 billion. The deal is seen as part of Bristol-Myers' strategy to leverage China's efficiency in early-stage drug development. Under the agreement, Bristol-Myers will license certain drug candidates from Hengrui, obtaining global development and commercialization rights. The potential $15.2 billion value includes upfront payments, development and commercial milestones, and royalties. This collaboration reflects Bristol-Myers' efforts to strengthen its portfolio and benefit from China's biotechnology ecosystem. Hengrui, one of China's leading pharmaceutical companies, aims to expand its global market access through the deal. No official announcement has been made regarding the financial details of the agreement or which drug candidates are covered. However, such large-scale licensing deals are a common strategy in the pharmaceutical industry for sharing R&D costs and distributing risks. This is not investment advice.